These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 19356746)

  • 21. Generation of protection against Francisella novicida in mice depends on the pathogenicity protein PdpA, but not PdpC or PdpD.
    Chou AY; Kennett NJ; Nix EB; Schmerk CL; Nano FE; Elkins KL
    Microbes Infect; 2013 Nov; 15(12):816-27. PubMed ID: 23880085
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Murine survival of infection with Francisella novicida and protection against secondary challenge is critically dependent on B lymphocytes.
    Chou AY; Kennett NJ; Melillo AA; Elkins KL
    Microbes Infect; 2017 Feb; 19(2):91-100. PubMed ID: 27965147
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Minimal requirements for murine resistance to infection with Francisella tularensis LVS.
    Elkins KL; Rhinehart-Jones TR; Culkin SJ; Yee D; Winegar RK
    Infect Immun; 1996 Aug; 64(8):3288-93. PubMed ID: 8757866
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Recovery from mouse hepatitis virus infection depends on recruitment of CD8(+) cells rather than activation of intrahepatic CD4(+)alphabeta(-)TCR(inter) or NK-T cells.
    Lamontagne L; Lusignan S; Page C
    Clin Immunol; 2001 Dec; 101(3):345-56. PubMed ID: 11726227
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Expansion and retention of pulmonary CD4
    Roberts LM; Wehrly TD; Crane DD; Bosio CM
    Vaccine; 2017 May; 35(19):2575-2581. PubMed ID: 28372827
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Temporal Requirement for Pulmonary Resident and Circulating T Cells during Virulent
    Roberts LM; Wehrly TD; Ireland RM; Crane DD; Scott DP; Bosio CM
    J Immunol; 2018 Aug; 201(4):1186-1193. PubMed ID: 29980611
    [TBL] [Abstract][Full Text] [Related]  

  • 27.
    Chandler CE; Harberts EM; Laemmermann T; Zeng Q; Opene BN; Germain RN; Jewell CM; Scott AJ; Ernst RK
    Infect Immun; 2018 Sep; 86(9):. PubMed ID: 29986891
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Functional Heterogeneity and Antimycobacterial Effects of Mouse Mucosal-Associated Invariant T Cells Specific for Riboflavin Metabolites.
    Sakala IG; Kjer-Nielsen L; Eickhoff CS; Wang X; Blazevic A; Liu L; Fairlie DP; Rossjohn J; McCluskey J; Fremont DH; Hansen TH; Hoft DF
    J Immunol; 2015 Jul; 195(2):587-601. PubMed ID: 26063000
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Galectin-3 functions as an alarmin: pathogenic role for sepsis development in murine respiratory tularemia.
    Mishra BB; Li Q; Steichen AL; Binstock BJ; Metzger DW; Teale JM; Sharma J
    PLoS One; 2013; 8(3):e59616. PubMed ID: 23527230
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Oral live vaccine strain-induced protective immunity against pulmonary Francisella tularensis challenge is mediated by CD4+ T cells and antibodies, including immunoglobulin A.
    Ray HJ; Cong Y; Murthy AK; Selby DM; Klose KE; Barker JR; Guentzel MN; Arulanandam BP
    Clin Vaccine Immunol; 2009 Apr; 16(4):444-52. PubMed ID: 19211773
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Innate and adaptive immunity to Francisella.
    Elkins KL; Cowley SC; Bosio CM
    Ann N Y Acad Sci; 2007 Jun; 1105():284-324. PubMed ID: 17468235
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Administration of a synthetic TLR4 agonist protects mice from pneumonic tularemia.
    Lembo A; Pelletier M; Iyer R; Timko M; Dudda JC; West TE; Wilson CB; Hajjar AM; Skerrett SJ
    J Immunol; 2008 Jun; 180(11):7574-81. PubMed ID: 18490759
    [TBL] [Abstract][Full Text] [Related]  

  • 33. CD4-CD8- T cells control intracellular bacterial infections both in vitro and in vivo.
    Cowley SC; Hamilton E; Frelinger JA; Su J; Forman J; Elkins KL
    J Exp Med; 2005 Jul; 202(2):309-19. PubMed ID: 16027239
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Intranasal interleukin-12 treatment for protection against respiratory infection with the Francisella tularensis live vaccine strain.
    Duckett NS; Olmos S; Durrant DM; Metzger DW
    Infect Immun; 2005 Apr; 73(4):2306-11. PubMed ID: 15784575
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Rapid dissemination of Francisella tularensis and the effect of route of infection.
    Ojeda SS; Wang ZJ; Mares CA; Chang TA; Li Q; Morris EG; Jerabek PA; Teale JM
    BMC Microbiol; 2008 Dec; 8():215. PubMed ID: 19068128
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Francisella novicida LPS has greater immunobiological activity in mice than F. tularensis LPS, and contributes to F. novicida murine pathogenesis.
    Kieffer TL; Cowley S; Nano FE; Elkins KL
    Microbes Infect; 2003 Apr; 5(5):397-403. PubMed ID: 12737995
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Initial delay in the immune response to Francisella tularensis is followed by hypercytokinemia characteristic of severe sepsis and correlating with upregulation and release of damage-associated molecular patterns.
    Mares CA; Ojeda SS; Morris EG; Li Q; Teale JM
    Infect Immun; 2008 Jul; 76(7):3001-10. PubMed ID: 18411294
    [TBL] [Abstract][Full Text] [Related]  

  • 38. TCR ligation on CD8+ T cells creates double-negative cells in vivo.
    Mehal WZ; Crispe IN
    J Immunol; 1998 Aug; 161(4):1686-93. PubMed ID: 9712032
    [TBL] [Abstract][Full Text] [Related]  

  • 39. CD8α
    Zhang W; Xu L; Zhang X; Xu J; Jin JO
    Immunology; 2020 Apr; 159(4):404-412. PubMed ID: 31909831
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Intranasal vaccination induces protective immunity against intranasal infection with virulent Francisella tularensis biovar A.
    Wu TH; Hutt JA; Garrison KA; Berliba LS; Zhou Y; Lyons CR
    Infect Immun; 2005 May; 73(5):2644-54. PubMed ID: 15845466
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.